Application of wedelolactone in preparation of medicaments or healthcare products for treating osteoporosis

A technology for wedelide and osteoporosis, which is applied in the application field of wedelide, can solve the problems of few pharmacological studies of the monomer compound wedelide, and the failure to determine the anti-osteoporosis effect, so as to achieve a wide range of applications, Active effect

Inactive Publication Date: 2015-03-18
DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

) It has also been reported that the ethanol extract of Wedelia calendula has a significant anti-osteoporosis effect on the ovariectomized rat model (Annie S, Prabhu RG, Malini S. Activity of Wedelia calendulacea Less in post-menopausal osteoporosis[J]. Phytomedicine, 2006, 13 (1-2): 43.) However, none of the above reports can determine which ingredient has a definite anti-osteoporosis effect
At the same time, there are few pharmacological studies on the monomeric compound wedelolactone, mainly anti-hepatotoxicity (Wong SM, Antus S, Gottsegen A, et al. Wedelolactone and coumestan derivatives as new antihepatotoxic and antiphlogistic principles[J].
[0005] Arzneimittelforschung, 1988, 38 (5): 661.) and anti-tumor effect (Lin FM, Chen LR, Lin EH, et al.Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells[J].Carcinogenesis, 2007 , 28(12): 2521.) Whether it has anti-osteoporosis effect has not been reported in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of wedelolactone in preparation of medicaments or healthcare products for treating osteoporosis
  • Application of wedelolactone in preparation of medicaments or healthcare products for treating osteoporosis
  • Application of wedelolactone in preparation of medicaments or healthcare products for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Experimental materials and reagents: Wedelia lactone was extracted and prepared by our laboratory from Eclipta prostrata, HPLC purity ≥98%, batch 20111026.

[0017] The cell line used was mouse preosteoclast RAW264.7, purchased from the Cell Bank of the Type Culture Collection Committee of the Chinese Academy of Sciences (Shanghai), cultured in DMEM (Gibco) containing 10% fetal bovine serum (Hangzhou Sijiqing), 0.05 % Trypsin (Solarbio) digestion and passage. Place cells at 37°C, 5% CO 2 , Cultivate in an incubator with saturated humidity. Reagents used: MTT, RANK Ligand from mouse (RANKL), anti-tartrate acid phosphatase kit (TRAP kit) are all sigma products, estradiol (E 2 ) Purchased from the National Institute for the Control of Pharmaceutical and Biological Products. Instruments used: carbon dioxide incubator (HEAL FORCE), ultra-clean workbench (HEAL FORCE), microplate reader (sunrise, TECAN), inverted microscope (Olymbus).

[0018] experimental method:

[0019] MTT met...

Embodiment 2

[0025] The batch of wedelia lactone is 20130123, and the number of cells inoculated in each well of the 96-well plate is 15,000. The reagents, method steps and data processing used in the experiment are the same as in Example 1.

[0026] Table 2. Effects of estradiol and wedelia lactone on the proliferation of RAW264.7 cells

[0027]

[0028] Note: Compared with the negative control group 1) P2) P3) P<0.001

[0029] TRAP kit detects the activity of TRAP enzyme in RAW264.7 cells induced by RANKL: Wedelia lactone batch is 20111026. RAW264.7 cells were seeded into 96-well plates at 8000 cells per well, 50μL per well, and cultured overnight. In the RANKL control group, 50μL of RANKL prepared with serum-free medium and 100μL of serum-free medium were added to each well, and the Wedelia lactone test group was added with 50μL of RANKL prepared in serum-free medium and 100μL of Wedelia lactone, E 2 In the experimental group, 50μL of RANKL and E prepared in serum-free medium were added to e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides new use of wedelolactone and particularly relates to application of wedelolactone in preparation of medicaments or healthcare products for treating osteoporosis. Experiments show that wedelolactone is capable of obviously inhibiting proliferation of preosteoclast and inhibiting tartrate-resistant acid phosphatase activity of the preosteoclast; by inhibiting the proliferation and the differentiation of the preosteoclast, the bone loss is reduced, so that wedelolactone has anti-osteoporosis activity and can be used for preparing the medicaments or the healthcare products for treating the osteoporosis.

Description

Technical field [0001] The present invention relates to the application of wedelia lactone. That is, the application of wedelia lactone in the preparation of medicines and health products for the prevention and treatment of osteoporosis. Background technique [0002] Osteoporosis ranks seventh in the world's common and frequently-occurring diseases, and it occurs frequently in the elderly. According to expert estimates, the current prevalence of osteoporosis in the population over 60 years old in my country is about 50% for women and 20% for men. There are about 90 million patients with osteoporosis. With the increasing aging of our country, the prevention and treatment of osteoporosis has become a major project. Although experts at home and abroad attach great importance to the prevention and treatment of this disease, there is still a lack of effective preventive and therapeutic drugs for this disease. [0003] Therapeutic drugs for osteoporosis are classified into bone resorpt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P19/10A23L1/29A23L33/00
CPCA61K31/37
Inventor 肖红斌程孟春刘艳秋王莉
Owner DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap